Launch of PulseSight Therapeutics: advancing non-viral gene therapy for eye diseases
February 28, 2024PulseSight Therapeutics SAS, a biotech company, launches with funding from Pureos Bioventures and ND Capital. It aims to validate its innovative delivery platform by advancing drugs for age-related macular diseases.
PulseSight uses a non-viral gene therapy ocular platform to treat major eye diseases. The lead program, PST-809, targets wet AMD by reducing vascular leakage and promoting healing. Another program, PST-611, addresses geographic atrophy (GA) in late-stage dry AMD.
The company’s seed funding comes from venture capital investors with significant ophthalmology experience. Dirk Sauer, previously of Novartis, joins as independent chair.
CEO Judith Greciet, a seasoned pharma-biotech executive, leads the experienced leadership team. Greciet expressed enthusiasm about joining the company. She highlighted the validated delivery platform and two advanced non-viral gene therapy programs. Greciet emphasized the unique efficacy, safety, and durability of the company’s proprietary approach. She looks forward to collaborating with the experienced team and board to shape the company’s future.
PulseSight aims to make a significant impact in non-viral gene therapy in ophthalmology.